EMVision develops the emu™, a portable, non‑invasive neuroimaging device that uses ultra‑high frequency radio signals and AI to produce rapid bedside brain scans. The company is scaling production and clinical trials to support regulatory approval and adoption in the US, with market entry for the emu™ planned for next year. EMVision is also developing a backpack‑sized first responder scanner (under 10 kg) intended for road and air ambulances to enable paramedics to scan suspected stroke patients on site. The company’s pipeline targets intensive care units, stroke and neurology wards, and rural emergency departments where CT/MRI access is limited. EMVision holds offices in Sydney and Brisbane and has an OEM supply partnership with Keysight that grants exclusivity for the VNA "fast sweep" feature. The emu™ and first responder devices are not yet FDA‑evaluated and are restricted to authorized sites in controlled clinical investigations. New capital from Keysight is intended to accelerate clinical trials, expand production capacity, and support commercialization efforts in the US.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2024